Azitra, Inc.

AMEX:AZTR

Biotechnology

Healthcare
$1.53 +113.99%

+$0.82 today

Market cap
$92.72M
Beta
-1.04
P/E (TTM)
-1.2
EPS (TTM)
-$0.64
52W Low $0.05High $2.13

Volume 146.25M

Average 11.12M

AZTR Account Payables

Amounts the company owes suppliers for goods and services received.

Azitra, Inc.AMEX: AZTR

Account Payables · Q2 FY2026 · quarter ended Jun 2026

Account payables falls 21.7% from a year ago

Account payables stood at $497.99K at the end of Q2 FY2026, down 21.7% from a year earlier and down 46.6% from the prior quarter. Over 3 fiscal years it compounded at -20.2% a year.

Context

  • Account payables amounted to 5.6% of total assets at the end of Q2 FY2026, down 10.5 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps falling in the next quarterly balance sheet after a -21.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$497.99K-46.6% QoQ
Last fiscal yearDec 2025
$399.36K-18.5% YoY
Year agoJun 2025
$635.84K-21.7% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.7%——
1 year-18.5%——
3-year CAGR-20.2%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
399.36K USD
Year-over-year change
-18.5%
4-year CAGR
-13.6%

Account Payables vs competitors

How AZTR compares with its peers on the latest reported figures

  • AZTR's Jun 2026 account payables of $497.99K is the lowest of the 2 companies compared; the peer median is $557.37K.
  • Its year-over-year change of -21.7% is the highest of 2, against a peer median of -57.5%.
  • Account payables amounts to 5.6% of total assets for AZTR, versus a peer median of 25.6%.
AZTR Competitors Peer median
Account Payables for AZTR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INDPIndaptus Therapeutics, Inc.Mar 2026$557.37K -57.5%-26.6%25.6%
AZTRAzitra, Inc.Jun 2026$497.99K -21.7%-20.2%5.6%
Peer median (excluding AZTR) $557.37K-57.5%-26.6%25.6%

Competitors are the stored peer set for AZTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents8.04M3.49M1.8M4.55M2.07M
Short-term Investments00000
Net Receivables334.18K266.21K223.47K101.9K141.3K
Inventory00000
Other Current Assets0216.89K67.86K4.11K0
Total Current Assets8.49M4.14M2.54M5.23M3.02M
Property, Plant & Equipment (Net)946.68K1.96M1.58M1.21M962.08K
Goodwill00000
Intangible Assets97.69K219.57K210.88K246.42K316.67K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets668.23K848.34K789.99K678.22K727.31K
Total Non-current Assets1.71M3.03M2.58M2.13M2.01M
Total Assets10.2M7.17M5.12M7.36M5.03M
Account Payables717.8K784.69K897.27K490.26K399.36K
Short-term Debt00000
Tax Payables1.3K0011.57K6.26M
Deferred Revenue15K156K000
Other Current Liabilities43.47K27.08K145.04K32.97K236.86K
Total Current Liabilities1.21M2.22M1.6M1.38M1.07M
Long-term Debt992.02K6.6M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities33.77M33.76M35.45K3810
Total Non-current Liabilities34.76M41.21M599.15K284.65K156.19K
Total Liabilities35.97M43.43M2.2M1.66M1.22M
Common Stock1041041.21K7631.07K
Retained Earnings(26.63M)(37.31M)(48.6M)(57.57M)(68.52M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(25.77M)(36.26M)2.91M5.7M3.8M
Total Debt992.02K7.73M885.95K555.51K422.08K
Net Debt(7.05M)4.24M(910.04K)(4M)(1.65M)

Azitra, Inc.

AMEX:AZTR

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.